Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 543-549

  Maia, Hugo ^a   Haddad, Clarice ^a   Pinheiro, Nathanael ^a   Casoy, Julio ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Cyclo oxygenase 2; Drospirenone; Dysmenorrhea; Endometriosis; Resveratrol

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; RESVERATROL;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ENDOMETRIUM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LAPAROSCOPY; LOW DRUG DOSE; MONOTHERAPY; OPEN STUDY; PAIN ASSESSMENT; PELVIS PAIN SYNDROME; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84867502374     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Attar E. Aromatase and other steroidogenic genes in endometriosis. Translational aspects. Hum Reprod Update. 2006;12:49-56.
2. Maia H Jr, Haddad C, Casoy J. Correlation between aromatase expression in the eutopic endometrium and the presence of endometriosis. Int J Women's Health. 2012;4:61-65.
3. Maia H Jr, Casoy J, Valente Filho J. Is aromatase expression in the endometrium the cause of endometriosis and its related infertility? Gynecol Endocrinol. 2009;25:253.
4. Guo SW. Nuclear factor-kappaB (NF-kappaB): an unsuspected major culprit in the pathogenesis of endometriosis that is still at large? Gynecol Obstet Invest. 2007;63:71-97.
5. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005;84:300-304.
6. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 2000;6:413-418.
7. Maia H Jr, Casoy J, Correia T, et al. The effects of oral contraceptives on aromatase expression in the eutopic endometrium of patients endometriosis. Gynecol Endocrinol. 2008;24:123-128.
8. Maia H Jr, Casoy J. Non contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care. 2008;13:17-24.
9. Fechner S, Husen B, Thole H, et al. Expression and regulation of estrogen converting enzymes in ectopic human endometrial tissue. Fertil Steril. 2007;88 Suppl:1029-1038.
10. Yamanak K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stroma cells in spheroid cultures. Fertil Steril. 2012;97:477-482.
11. Hatok J, Zubor P, Galo S, et al. Endometrial aromatase mRNA as a possible screening tool for advanced endometriosis and adenomyosis. Gynecol Endocrinol. 2010;27:331-336.
12. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as estrogen dependent diseases. J Steroid Biochem Mol Biol. 2002;83:149-155.
13. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic disease. Cell Cycle. 2008;7:1020-1035.
14. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84:106-112.
15. Mabrouk M, Solfrini S, Frascà C, et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol. 2012;28:451-454.
16. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short term and long term effectiveness. Am J Obstet Gynecol. 1981;139:645-654.
17. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel intrauterine releasing device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305-309.
18. Fontein DB, Nortier JW, Liefers GJ, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38: 110-117.
19. Wang Y, Leung LK. Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells. Toxicol Lett. 2007;173: 175-180.
20. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res. 1999;25:65-77.
21. Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem. 2011;286:11492-11505.
22. Ryu J, Ku BM, Lee YK, et al. Resveratrol reduces TNF-a-induced U373M human glioma cell invasion through regulating NF-κB activation and uPA/uPAR expression. Anticancer Res. 2011;31:4223-4230.
23. Noble LS. Prostaglandin E2 stimulates aromatase activity in endometriosis derived stromal cells. J Clin Endocrinol Metab. 1997;82:600-606.
24. Maia H Jr, Casoy J, Correia T. Activation of NF-KappaB and Cox-2 expression is associated with breakthrough bleeding in patients using oral contraceptives in extended regimens. Gynecol Endocrinol. 2010;26: 265-269.